Polaris Venture Management Co. V, L.L.C.

CIK 1439589 · last filed 2020-05-06

Polaris Venture Management Co. V, L.L.C. is a corporate insider who has filed 9 SEC Form 4 insider transactions across 6 companies since 2014. The most recent filing, for LYRA, was dated May 6, 2020. Across all open-market trades the lifetime net is −$95.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $39.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$39.67M

Companies

6

Total Filings

9

Lifetime Open-Market Net

-$95.40M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Lyra Therapeutics, Inc. (LYRA) Delisted	10%+ Owner	21,245	$0.70	$14.9K	$5.92M	1	2020-05-06
PHR	10%+ Owner	3,101,386	$12.51	$38.80M	-$61.19M	1	2019-12-18
CDLX	10%+ Owner	219,748	$3.65	$802.1K	-$33.40M	4	2019-06-11
T2 Biosystems, Inc. (TTOO) Delisted	10%+ Owner	16	$0.00	$0	-$2.49M	1	2015-07-14
LIFE	10%+ Owner	2,332	$31.61	$73.7K	$0	1	2015-05-14
GENOCEA BIOSCIENCES, INC. (GNCA) Delisted	10%+ Owner	258,111	$0.00	$155	-$4.24M	1	2014-08-12

Recent Filings

9 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2020-05-06	Lyra Therapeutics, Inc. (LYRA) Delisted	Mixed	+7,705,964	$7.00M	EDGAR
2019-12-18	PHR	Sell (S)	−2,499,847	-$61.19M	EDGAR
2019-06-11	CDLX	Sell (S)	−500,000	-$12.81M	EDGAR
2019-06-06	CDLX	Sell (S)	−376,420	-$9.07M	EDGAR
2019-05-30	CDLX	Sell (S)	−500,000	-$11.52M	EDGAR
2018-02-15	CDLX	Conv (C)	+13,181,310	$0	EDGAR
2015-07-14	T2 Biosystems, Inc. (TTOO) Delisted	Sell (S)	−149,990	-$2.49M	EDGAR
2015-05-14	LIFE	Conv (C)	+9,139,960	$0	EDGAR
2014-08-12	GENOCEA BIOSCIENCES, INC. (GNCA) Delisted	Sell (S)	−318,970	-$4.24M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.